Share this article
Share this article
PHILADELPHIA, and BIRMINGHAM, Ala., April 12, 2021 /PRNewswire/ Treovir, an immuno-oncology company that is developing and plans to commercialize G207 for recurrent glioblastoma in children, announced today that G207, an oncolytic HSV immunotherapy, was well tolerated with evidence of clinical effectiveness in a phase 1 study of 12 pediatric patients with recurrent high-grade glioma. Data from the phase 1 study (NCT02457845) are being presented by Gregory Friedman, M.D., professor in the Department of Pediatrics at the University of Alabama at Birmingham, during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15. Data from this trial have been published in the
Genetically modified HERPES virus doubles life expectancy of children with brain tumors dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
email article
Treatment with an oncolytic immunovirotherapy alone or with radiation appeared safe and effective in a phase I study of children and adolescents with heavily pretreated high-grade glioma.
Eleven of 12 patients with progressive or recurrent supratentorial high-grade gliomas achieved radiographic, neuropathological, or clinical responses following treatment with G207, a genetically engineered herpes simplex virus (HSV) delivered intratumorally via catheter, Gregory Friedman, MD, of the University of Alabama at Birmingham, reported at the American Association for Cancer Research virtual meeting.
The treatment was associated with few toxicities, and the median overall survival (OS) reached 12.2 months (95% CI 8.0-16.4), which compares favorably to an established median OS of 5.6 months in the recurrent setting. Four of the 12 patients (36%) have survived beyond 18 months, exceeding the typical life expectancy for newly diagnosed cases.
Unusual treatment shows promise for kids with brain tumours ctvnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ctvnews.ca Daily Mail and Mail on Sunday newspapers.
The study used genetically modified herpes virus to treat gliomas, which account for 8% to 10% of childhood brain tumors and often return after surgery, chemo or radiation.